A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

NCT04820686 ↗

Phase 2 Terminated 65 enrolled Assembly Biosciences Arbutus Biopharma Corporation · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

Timeline

Start: 2021-05-07
Primary completion: 2023-03-30
Completion: 2023-03-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol. 2021 Aug;49:41-51. doi: 10.1016/j.coviro.2021.04.009. Epub 2021 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imdusiran	Small interfering RNA (siRNA)	60 mg	Subcutaneous
Subject	VBR	Unknown	300 mg	Oral
Background	Entecavir	Small molecule	—	Oral
Background	Tenofovir disoproxil fumarate	Small molecule	—	Oral
Background	tenofovir alafenamide	Small molecule	—	Oral